SMARTSTREAM-TECHNOLOGIES
12.10.2021 09:02:08 CEST | Business Wire | Press release
SmartStream Technologies, the financial Transaction Lifecycle Management (TLM® ) solutions provider, today announces that Fisher & Paykel Appliances, the global manufacturer of household appliances, operating in over 50 countries, has signed with SmartStream Air - providing the firm’s finance team with cloud-native, AI technology for bank reconciliations.
As a leading appliance manufacturer headquartered in New Zealand, Fisher & Paykel Appliances approached SmartStream to evaluate their data management and reconciliations tooling. SmartStream Air is agnostic to structured data formats requiring zero IT skillset to use, and will automate the finance division’s data reconciliation processing, at speed. The AI solution will easily integrate with Fisher & Paykel Appliances’ existing systems enabling them to perform additional analytics on reconciled data. In addition, it will provide business intelligence by connecting to third-party tools already deployed in-house.
SmartStream Air’s software as a service (SaaS) ease of deployment in numerous locations was a key deciding factor as Fisher & Paykel Appliances will look to roll out the product in New Zealand, followed by multiple locations in Asia Pacific and then globally. The company was looking to automate and enhance their currently manual reconciliation operating model to support their growing business volumes globally.
The process to proof-of-concept for SmartStream Air was quick in comparison to the three other competitor reconciliation solutions that were under consideration. As a self-service, AI enabled, cloud-native application, agnostic to structured data formats and data reconciliation types, with little configuration to setup, the go-live was immediate with higher levels of productivity to meet the growing business at Fisher & Paykel.
Nicole Adamson, Senior Corporate Controller, Fisher & Paykel, states: “We are pleased to partner with SmartStream, it is in our interest to keep up with the latest technologies and always improve our internal processes and productivity. We needed to move away from the manual operations to an automated data reconciliation model, which eliminates operational risk, whilst being able to scale volumes more cost-effectively. We felt SmartStream Air was the right choice to help us achieve this objective”.
Victoria Harverson, Global Head of Business Development for SmartStream Air, comments: “We are delighted to have Fisher and Paykel as a SmartStream Air customer. This partnership is significant as it recognises our deepening footprint in New Zealand, whilst also establishing a new relationship with a customer in the manufacturing sector. SmartStream Air is perfect for this type of operating model and really showcases how easy and cost-effective it can be for a company finance team to quickly control risk and see real tangible ROI by leveraging the latest self-service AI tooling”.
With SmartStream Air users can use the power of AI to autonomously build and learn data matching behaviour, transforming typical data reconciliation tasks – reducing the time it takes to just seconds. Speed of go-to-market and scalability was also a winning factor as SmartStream Air has been designed to be live the same day and is built for performance when it comes to high-volume processing.
Ends
About Fisher & Paykel
Fisher & Paykel Appliances has been designing products since 1934 and has grown into a global company with products sold in more than 50 countries around the world.
Our design heritage is founded on a pioneering spirit and a culture of curiosity. We’ve built our legacy with a future focus that still stays true to the fundamentals of sustainable design. We believe technology should always begin with the people who use it. This has seen us challenge conventional appliance design to create products that deliver to genuine human need.
Our ongoing research and development is backed by a culture of open innovation, collaboration and curiosity – one that seeks to uncover insights and ideas that connect with our customers and respect our planet.
About SmartStream
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005110/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom